The new quest in CTLA-4 insufficiency: How to immune modulate effectively? - 03/02/22
Doi : 10.1016/j.jaci.2021.11.020
Emma Westermann-Clark, MD, MA a, b, Mark Ballow, MD b, c, Jolan E. Walter, MD, PhD b, c, d, ⁎ 
a Division of Allergy/Immunology, Department of Medicine, University of South Florida Morsani College of Medicine, Tampa, Fla
b Division of Allergy/Immunology, Department of Pediatrics, University of South Florida Morsani College of Medicine, St Petersburg, Fla
c Division of Allergy/Immunology, Department of Pediatrics, Johns Hopkins All Children’s Hospital, St Petersburg, Fla
d Division of Allergy and Immunology, Massachusetts General Hospital for Children, Boston, Mass
∗Corresponding author: Jolan E. Walter, MD, PhD, University of South Florida, 601 4th St South, Children’s Research Institute 4008, St Petersburg, FL 33701.University of South Florida601 4th St SouthChildren’s Research Institute 4008St PetersburgFL33701
Key words : CTLA-4 insufficiency, abatacept, treatment, immune dysregulation, transendocytosis
Le texte complet de cet article est disponible en PDF.
| Supported in part by the Robert A. Good Endowed Chair from the Foundation of University of South Florida. |
|
| Disclosure of potential conflict of interest: E. Westermann-Clark's spouse has received grants or led investigator-initated trials with support from Kite/Gilead, Jazz, and Servier; he has done consulting and education work for Amgen, Pfizer, Novartis, BMS/Celgene/Juno, Kite/Gilead, Precision Biosciences, Jazz, Acrotech, Beigene, Pharmacyclics, Adaptive, Century Therapeutics, Autolus; and he is on a steering committee for PeproMene Bio. J. E. Walter is local principal investigator for sponsored studies by Janssen, Takeda, Octapharma, Chiesi (formerly Leadiant), MustangBio, and ADMA Biologicals, and he has consulted for CSL Behring, Takeda, X4-Pharmaceuticals, Pharming, Regeneron, Grifols, ADMA Biologicals, and Enzyvant outside the submitted work. M. Ballow has been an advisory board member for CSL Behring, Grifols, and Takeda (formerly Shire); a consultant for Grifols; speaker bureau participant for Takeda (formerly Shire) and CSL Behring; consulting medical director for the Immune Deficiency Foundation; and a member of the data safety monitoring board for CSL Behring, Prometric BioTherapeutics, Inc, Green Cross, Glenmark Pharmaceuticals, Grifols, ADMA Biologicals, Pharming, and Regeneron outside the submitted work. |
© 2021
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 149 - N° 2
P. 543-546 - février 2022 Retour au numéro
Article précédent
- The importance of using core outcome measures during therapeutic studies of eosinophilic esophagitis
- David A. Hill
- Μένος: Power, life force, and purpose in mentoring
- Kathleen E. Sullivan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?